ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement (ENAVO-TAVR)

Duk-Woo Park, MD

Status and phase: Enrolling; Phase 4

Conditions: Aortic Valve Stenosis; Heart Failure

Treatments: Drug: Standard-of-Care; Drug: Enavogliflozin

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT05672836

AMCCV2023-01

Details and patient eligibility

About

The goal of this trial is to to determine whether use of a novel SGLT2 inhibitor, Enavogliflozin 0.3 mg once daily is superior to placebo, when added to standard-of-care, in reducing the composite of major cardiovascular events and Heart Failure events (hospitalization for Heart Failure or urgent Heart Failure visit) among patients who underwent transcatheter aortic valve replacement for severe aortic stenosis and with heart failure with preserved ejection fraction.

Enrollment: 1,040 estimated patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients aged ≥19 with symptomatic aortic stenosis who underwent successful transcatheter aortic valve replacement (TAVR)* (either native valve or valve in valve with any approved/marketed device).

* A successful TAVI is defined as device success according to the VARC-2(Valve Academic Research Consortium 2) and VARC-3 criteria:

1. correct positioning of a single prosthetic heart valve into the proper anatomical location AND

2. intended performance of the prosthetic heart valve (mean aortic valve gradient <20 mmHg, peak velocity <3 m/s, no moderate or severe prosthetic valve regurgitation) AND

3. absence of periprocedural complications (any type of stroke, life-threatening bleeding, acute coronary artery obstruction requiring intervention, major vascular complication requiring intervention, unresolved acute valve thrombosis, or any requirement of a repeat procedure).

4. Heart Failure with Mildly Reduced or Preserved Ejection Fraction

5. Left ventricular ejection fraction (LVEF) ≥40%

6. structural heart disease_Left ventricular hypertrophy (LVH) or Left atrial enlargement

   A. Left ventricular hypertrophy (LVH) with septal thickness or posterior wall thickness ≥ 1.1 cm or

   B. Left atrial (LA) enlargement with at least one of the following: LA width (diameter) ≥3.8 cm or LA length ≥ 5.0 cm, or LA area ≥ 20cm2, or LA volume ≥ 55mL or LA volume index ≥ 29mL/m.

7. NT-proBNP ≥ 300 pg/mL (for patients without ongoing atrial fibrillation) or NT-proBNP must be ≥ 600 pg/mL (for patients with ongoing atrial fibrillation).

8. Patients who voluntarily participated in the written agreement

Exclusion criteria

1. Acute decompensated Heart Failure (exacerbation of chronic Heart Failure) requiring intravenous diuretics, vasodilators, inotropic agents, or mechanical support, or hemodynamic instability following the transcatheter aortic valve replacement procedure.

2. Currently receiving therapy with an SGLT2 inhibitor within 4 weeks prior to randomization; discontinuation of current use of SGLT2 inhibitor for the purposes of study enrolment is not permitted.

3. Known allergy, hypersensitivity, or previous intolerance to an SGLT2 inhibitors.

4. HF with reduced ejection fraction (LVEF <40%).

5. Type 1 diabetes mellitus or diabetes ketoacidosis.

6. Chronic cystitis and/or recurrent urinary tract infection (≥2 times within 1 year).

7. Stroke or transient ischemic attack within 12 weeks prior to enrollment.

8. Symptomatic persistent hypotension and/or a systolic blood pressure (SBP) < 95 mm Hg at screening or at randomization.

9. SBP ≥180 mmHg irrespective of treatment or SBP ≥160 mmHg with at least ≥3 antihypertensive drugs at screening or randomization.

10. Heart failure due to any of the following causes; known infiltrative cardiomyopathy (e.g. amyloid, sarcoid, lymphoma, endomyocardial fibrosis, haemochromatosis, Fabry disease), active myocarditis, constrictive pericarditis, cardiac tamponade, known hypertrophic obstructive cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVD), or uncorrected primary valvular disease.

11. Severe renal insufficiency (eGFR <30 ml/min/1.73 m2 of body-surface area based on the Modification of Diet in Renal Disease (MDRD) formula) or end-stage renal disease or requiring dialysis at the time of screening.

12. Acute or chronic liver disease with severe impairment of liver function (e.g., ascites, esophageal varices, coagulopathy) or serum levels of transminases or alkaline phosphatase more than two times the upper limit of normal at screening.

13. Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalization for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension.

14. Current or suspicious malignancy or history of malignancy within 5 years

15. Uncontrolled anaemia or haemoglobin <9g/dl

16. Uncontrolled hypothyroidism or arrhythmia or tachycardia

17. Current ongoing alcoholic or drug addict

18. Subjects with non-cardiac co-morbidities with life expectancy less than 12 months

19. Planned major high-risk operation after transcatheter aortic valve replacement (TAVR)

20. Women of childbearing age who have not reached a consensus on the use of highly effective contraception. Pregnancy or breastfeeding.

21. Participation in other clinical trials, However, where at least one or more conditions are satisfied, it could be an exception according to an investigator's discretion;

    • Participating in the observational study expected no effect on the safety and/or effectiveness evaluation of this trial.
    • Screening failed before any interventional factor is involved.
    • Participants who have completed their involvement in clinical trials and have surpassed a 4-week period since their last administration of the investigational drug.
    • Participated in academic trials like strategic or medical device comparison studies conducted under standard therapy provided that there is no additional risk or a specific procedure to a subject and no interference between this trial and other studies.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

1,040 participants in 2 patient groups, including a placebo group

Enavogliflozin Group

Experimental group

Description:

0.3 mg 1 tablet once daily

Treatment:

Drug: Enavogliflozin

placebo as add-on to standard of care treatment group

Placebo Comparator group

Description:

Placebo matching enavogliflozin

Treatment:

Drug: Standard-of-Care